News | Left Atrial Appendage (LAA) Occluders | October 13, 2016

SentreHeart Announces First Clinical Use of Eclipse Surgical LAA Closure Device

First procedures conducted in Krakow, Poland

SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland

October 13, 2016 — SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is approved and CE Marked in Europe for left atrial appendage (LAA) closure. Krzysztof Bartus, M.D., Ph.D., and associate professor of the Jagiellonian University, Department of Cardiovascular and Transplant Surgery in Krakow, Poland performed the procedures.

According to Bartus, “The procedures went exceedingly well. Complete closure was achieved in all cases. The ultra-low profile of the Eclipse improves visualization during placement, is easy to use and unlike other surgical solutions, does not require excessive grasping or manipulation of the left atrial appendage to close around its base.”

The Eclipse enables remote delivery of a 50mm pre-tied suture loop in a controlled and precise manner with immediate and complete LAA closure.

For more information: www.sentreheart.com


Related Content

News | Atrial Fibrillation

Sept. 11, 2024 — In the first national estimate in two decades, researchers at the University of California-San ...

Home September 11, 2024
Home
News | Atrial Fibrillation

July 24, 2024 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist ...

Home July 24, 2024
Home
News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
Subscribe Now